Novonesis (WBAG:NZYM) - Stock Price, News & Analysis

NZYM Stock Overview

Produces and sells industrial enzymes, microorganisms, and probiotics in Denmark, rest of Europe, North America, Asia Pacific, the Middle East, Africa, Latin America, and internationally.

About the company

NZYM fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	4/6
Past Performance	0/6
Financial Health	5/6
Dividends	0/6

Rewards

Earnings are forecast to grow 28.86% per year

Risk Analysis

Shareholders have been substantially diluted in the past year

Large one-off items impacting financial results

Profit margins (9.3%) are lower than last year (19.3%)

Novonesis A/S Competitors

Wanhua Chemical Group

SHSE:600309

CN¥253.4b

Asian Paints

NSEI:ASIANPAINT

₹3.1t

PPG Industries

NYSE:PPG

US$29.8b

DuPont de Nemours

NYSE:DD

US$35.9b

Price History & Performance

Summary of all time highs, changes and price drops for Novonesis
Historical stock prices
Current Share Price	DKK 64.04
52 Week High	DKK 64.08
52 Week Low	DKK 37.13
Beta	0.52
11 Month Change	4.64%
3 Month Change	12.27%
1 Year Change	69.64%
33 Year Change	8.18%
5 Year Change	69.78%
Change since IPO	52.69%

Recent updates

Shareholder Returns

	NZYM	AT Chemicals	AT Market
7D	5.3%	1.3%	-0.6%
1Y	69.6%	15.1%	6.9%

Return vs Industry: NZYM exceeded the Austrian Chemicals industry which returned 14.6% over the past year.

Return vs Market: NZYM exceeded the Austrian Market which returned 7% over the past year.

Price Volatility

Is NZYM's price volatile compared to industry and market?
NZYM volatility
NZYM Average Weekly Movement	2.4%
Chemicals Industry Average Movement	5.1%
Market Average Movement	3.5%
10% most volatile stocks in AT Market	5.8%
10% least volatile stocks in AT Market	1.7%

Stable Share Price: NZYM has not had significant price volatility in the past 3 months.

Volatility Over Time: NZYM's weekly volatility (2%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
1925	10,452	Ester Baiget	www.novonesis.com

Novonesis A/S produces and sells industrial enzymes, microorganisms, and probiotics in Denmark, rest of Europe, North America, Asia Pacific, the Middle East, Africa, Latin America, and internationally. The company offers protein solutions for the food and beverage industry. It also offers industrial hygiene, drain openers, hard surface, medical cleaning, septic tanks, ware washing, and professional laundry services.

Novonesis A/S Fundamentals Summary

How do Novonesis's earnings and revenue compare to its market cap?
NZYM fundamental statistics
Market cap	€29.66b
Earnings (TTM)	€282.79m
Revenue (TTM)	€3.04b

104.9x

P/E Ratio

9.7x

P/S Ratio

Is NZYM overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
NZYM income statement (TTM)
Revenue	€3.04b
Cost of Revenue	€1.62b
Gross Profit	€1.42b
Other Expenses	€1.14b
Earnings	€282.79m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

Nov 07, 2024

Earnings per share (EPS)	0.61
Gross Margin	46.66%
Net Profit Margin	9.29%
Debt/Equity Ratio	18.1%

How did NZYM perform over the long term?

See historical performance and comparison

Dividends

0.8%

Current Dividend Yield

108%

Payout Ratio

NZYM Stock Overview

Rewards

Risk Analysis

Novonesis A/S Competitors

SHSE:600309

CN¥253.4b

NSEI:ASIANPAINT

₹3.1t

NYSE:PPG

US$29.8b

NYSE:DD

US$35.9b

Price History & Performance

Recent News & Updates

First half 2024 earnings released: EPS: €0.14 (vs €0.67 in 1H 2023)

Novonesis Approves Interim Dividend for 2024, Payable on September 3, 2024

Novonesis Provides Sales Guidance for the Year 2024

Novozymes A/S Approves Dividend for the Last Four Months Ended December 31, 2023

Upcoming dividend of kr.2.00 per share

Novozymes A/S Proposes Dividend for the Last Four Months Ended December 31, 2023

Recent updates

First half 2024 earnings released: EPS: €0.14 (vs €0.67 in 1H 2023)

Novonesis Approves Interim Dividend for 2024, Payable on September 3, 2024

Novonesis Provides Sales Guidance for the Year 2024

Novozymes A/S Approves Dividend for the Last Four Months Ended December 31, 2023

Upcoming dividend of kr.2.00 per share

Novozymes A/S Proposes Dividend for the Last Four Months Ended December 31, 2023

Novonesis Provides Earnings Guidance for the Year 2024

Novonesis to Unveil Fit-for-Food Mood-Support Probiotic at Natural Product Expo West

Novozymes A/S Announces Board Appointments

Novozymes A/S to Report First Half, 2024 Results on Aug 28, 2024

Full year 2023 earnings released

New major risk - Shareholder dilution

Novozymes A/S (CPSE:NZYM B) completed the acquisition of Chr. Hansen Holding A/S (CPSE:CHR).

Novozymes A/S (CPSE:NZYM B) completed the acquisition of Chr. Hansen Holding A/S (CPSE:CHR).

Novozymes A/S to Report Fiscal Year 2023 Final Results on Apr 08, 2024

Novozymes Launches Quara(R) Lowp for Renewable Diesel Feedstock Pre-T Treatment

New minor risk - Share price stability

Novozymes Launches ProSilience™ HU58

Third quarter 2023 earnings released

Novozymes A/S Approves Interim Dividend, Payable on October 17, 2023

Novozymes A/S and Chr. Hansen Announce Executive Leadership Team and Organizational Structure

Now 21% undervalued after recent price drop

Now 21% undervalued after recent price drop

Second quarter 2023 earnings released: EPS: kr.2.19 (vs kr.2.92 in 2Q 2022)

Novozymes A/S Announces Change to the Executive Leadership Team

First quarter 2023 earnings released: EPS: kr.2.83 (vs kr.3.00 in 1Q 2022)

Upcoming dividend of kr.6.00 per share at 1.7% yield

Independent Chairman recently bought €135k worth of stock

Novozymes A/S Provides Earnings Guidance for the Year 2023

Full year 2022 earnings released

Novozymes A/S Announces Jørgen Buhl Rasmussen Decides Not to Seek Re-Election as Member of its Board of Directors

Investor sentiment deteriorated over the past week

Novozymes A/S (CPSE:NZYM B) agreed to acquire Chr. Hansen Holding A/S (CPSE:CHR).

Novozymes A/S (CPSE:NZYM B) agreed to acquire Chr. Hansen Holding A/S (CPSE:CHR).

Less than half of directors are independent

Third quarter 2022 earnings released

Novozymes A/S Provides Earnings Guidance for the Year 2022

Biotalys Nv and Novozymes A/S Announces Successful Evoca™ Feasibility Study

Novozymes A/S to Report Q3, 2022 Results on Nov 03, 2022

Now 20% undervalued after recent price drop

Now 21% undervalued after recent price drop

Second quarter 2022 earnings released: EPS: kr.2.92 (vs kr.2.85 in 2Q 2021)

Novozymes A/S Provides Earnings Guidance for the Year 2022

Novozymes A/S to Report Nine Months, 2023 Results on Oct 26, 2023

Novozymes Extends the Lifetime of Textiles with Sustainable Innovation

First quarter 2022 earnings released: EPS: kr.3.00 (vs kr.3.17 in 1Q 2021)

Less than half of directors are independent

Novozymes A/S Raises Full-Year Financial Guidance for 2022

Upcoming dividend of kr.5.50 per share

Full year 2021 earnings: Revenues in line with analyst expectations

Novozymes A/S Provides Revenue Guidance for 2022

Novozymes A/S (CPSE:NZYM B) completed the acquisition of a 60% stake in Synergia Life Sciences Pvt. Ltd. for DKK 1 billion.

Third quarter 2021 earnings released

Second quarter 2021 earnings released

Novozymes A/S Provides Earnings Guidance for the Full Year 2021

First quarter 2021 earnings released: EPS kr.3.17 (vs kr.2.89 in 1Q 2020)

Novozymes A/S Reaffirms Sales Guidance for the Year 2021

Univar Solutions and Novozymes® Partner to Bring Innovative, Sustainable Biotechnology Products to Customers in the United States and Canada

Novozymes Acquires Data Science Platform of Biota to Strengthen Microbiome R&D Capabilities in Probiotic Development